Literature DB >> 25710129

Post-infectious bronchiolitis obliterans in children: CT features that predict responsiveness to pulse methylprednisolone.

H M Yoon1, J S Lee, J-Y Hwang, Y A Cho, H-K Yoon, J Yu, S-J Hong, C H Yoon.   

Abstract

OBJECTIVE: Intravenous pulse methylprednisolone therapy (IPMT) is an important treatment option for post-infectious obliterative bronchiolitis (OB), although it must be used carefully and only in selected patients because of its drawbacks. This study evaluated whether CT and clinical features of children with post-infectious OB can predict their responsiveness to IPMT.
METHODS: We searched the medical records for patients (less than 18 years of age) who were diagnosed with post-infectious OB between January 2000 and December 2011. 17 children who received IPMT were included in this study. All underwent chest CT before and after IPMT. The radiological features seen on pre-treatment CT were recorded. The air-trapping area percentages on pre- and post-treatment CT images were determined. The nine patients who exhibited decreased air trapping on post-treatment CT scans relative to pre-treatment scans were classed as responders. The patient ages and time from initial pneumonia to IPMT were recorded.
RESULTS: All responders and only four non-responders had thickened bronchial walls before treatment (p = 0.029). The two groups did not differ significantly in terms of bronchiolitis, bronchiectasis or the extent of air trapping, although the responders had a significantly shorter median interval between initial pneumonia and IPMT (4 vs 50 months; p = 0.005) and were significantly younger (median, 2.0 vs 7.5 years; p = 0.048).
CONCLUSION: Immediate IPMT may improve the degree of air trapping in children with post-infectious OB if they show a thickened bronchial wall on CT. ADVANCES IN KNOWLEDGE: Children with post-infectious OB may respond favourably to IPMT when pre-treatment CT indicates bronchial-wall thickening.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25710129      PMCID: PMC4628466          DOI: 10.1259/bjr.20140478

Source DB:  PubMed          Journal:  Br J Radiol        ISSN: 0007-1285            Impact factor:   3.039


  11 in total

1.  High-resolution computed tomography in pediatric patients with postinfectious bronchiolitis obliterans.

Authors:  L Zhang; K Irion; N da Silva Porto; F Abreu e Silva
Journal:  J Thorac Imaging       Date:  1999-04       Impact factor: 3.000

Review 2.  Airway and blood vessel interaction during lung development.

Authors:  Alison A Hislop
Journal:  J Anat       Date:  2002-10       Impact factor: 2.610

Review 3.  The role of corticosteroids in respiratory diseases of children.

Authors:  F M de Benedictis; G J Canny; H Levison
Journal:  Pediatr Pulmonol       Date:  1996-07

4.  Bronchiolitis obliterans in children: a ghostly journey to the origin.

Authors:  F De Baets
Journal:  Allergol Immunopathol (Madr)       Date:  2011-08-26       Impact factor: 1.667

5.  Maintenance azithromycin therapy for bronchiolitis obliterans syndrome: results of a pilot study.

Authors:  Susan G Gerhardt; John F McDyer; Reda E Girgis; John V Conte; Stephen C Yang; Jonathan B Orens
Journal:  Am J Respir Crit Care Med       Date:  2003-04-02       Impact factor: 21.405

6.  Bronchiolitis obliterans in the 1990s in Korea and the United States.

Authors:  C K Kim; S W Kim; J S Kim; Y Y Koh; A H Cohen; R R Deterding; C W White
Journal:  Chest       Date:  2001-10       Impact factor: 9.410

7.  Azithromycin reverses airflow obstruction in established bronchiolitis obliterans syndrome.

Authors:  Bryan Yates; Desmond M Murphy; Ian A Forrest; Chris Ward; Robert M Rutherford; Andrew J Fisher; James L Lordan; John H Dark; Paul A Corris
Journal:  Am J Respir Crit Care Med       Date:  2005-06-23       Impact factor: 21.405

8.  Azithromycin reduces airway neutrophilia and interleukin-8 in patients with bronchiolitis obliterans syndrome.

Authors:  Geert M Verleden; Bart M Vanaudenaerde; Lieven J Dupont; Dirk E Van Raemdonck
Journal:  Am J Respir Crit Care Med       Date:  2006-06-01       Impact factor: 21.405

Review 9.  Bronchiolitis obliterans in children.

Authors:  Siby P Moonnumakal; Leland L Fan
Journal:  Curr Opin Pediatr       Date:  2008-06       Impact factor: 2.856

10.  Relationships between high-resolution computed tomography, lung function and bacteriology in stable bronchiectasis.

Authors:  Jin-Hwa Lee; Yoo-Kyung Kim; Hyon-Ju Kwag; Jung-Hyun Chang
Journal:  J Korean Med Sci       Date:  2004-02       Impact factor: 2.153

View more
  5 in total

1.  Effects of Inhaled Corticosteroids on Lung Function in Children With Post-infectious Bronchiolitis Obliterans in Remission.

Authors:  Haoqi Zheng; Xiuhua Yu; Yuquan Chen; Wenying Lin; Li Liu
Journal:  Front Pediatr       Date:  2022-05-10       Impact factor: 3.569

2.  Lung Clearance Index and Quantitative Computed Tomography of Post-Infectious Bronchiolitis Obliterans in Infants.

Authors:  Yoon Hee Kim; Hyun Joo Shin; In Suk Sol; Soo Yeon Kim; Jong Deok Kim; Haesung Yoon; Kyung Won Kim; Myung-Joon Kim; Mi-Jung Lee; Myung Hyun Sohn
Journal:  Sci Rep       Date:  2017-11-09       Impact factor: 4.379

3.  Quantitative CT and pulmonary function in children with post-infectious bronchiolitis obliterans.

Authors:  Jonghyeon Kim; Myung-Joon Kim; In Suk Sol; Myung Hyun Sohn; Haesung Yoon; Hyun Joo Shin; Kyung Won Kim; Mi-Jung Lee
Journal:  PLoS One       Date:  2019-04-01       Impact factor: 3.240

Review 4.  Postinfectious Bronchiolitis Obliterans in Children: Diagnostic Workup and Therapeutic Options: A Workshop Report.

Authors:  Silvija-Pera Jerkic; Folke Brinkmann; Alistair Calder; Alicia Casey; Megan Dishop; Matthias Griese; Geoffrey Kurland; Mandy Niemitz; Sylvia Nyilas; Dirk Schramm; Ralf Schubert; Michael Tamm; Stefan Zielen; Martin Rosewich
Journal:  Can Respir J       Date:  2020-01-30       Impact factor: 2.409

5.  Follow-up on the therapeutic effects of a budesonide, azithromycin, montelukast, and acetylcysteine (BAMA) regimen in children with post-infectious bronchiolitis obliterans.

Authors:  Tingting Weng; Xixi Lin; Leying Wang; Jiamei Lv; Lin Dong
Journal:  J Thorac Dis       Date:  2021-08       Impact factor: 2.895

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.